FORCE's eXamining the Relevance of Articles for You (XRAY) program looks behind the headlines of cancer news to help you understand what the research means for you.
XRAY is a reliable source of hereditary cancer research-related news and information.
Learn more about the XRAY program
All XRAYs
Relevance: High


Strength of Science: High


Research Timeline: Human Research


Study : Niraparib increases progression-free survival in patients with newly diagnosed ovarian cancer
Most relevant for: Women newly-diagnosed with ovarian cancer
This study looked at the effectiveness and safety of niraparib (Zejula), a PARP inhibitor, as maintenance therapy in newly diagnosed ovarian cancer patients who had a response to chemotherapy. (11/5/19)
Read More
Relevance: Medium-Low


Research Timeline: Human Research


Personal Story : A “flu shot” against breast cancer? Not so fast
Most relevant for: Women diagnosed with Ductal Carcinoma In Situ (DCIS)
There have been multiple reports in the media of a Florida woman who had a "shot" to treat her DCIS with a promising outcome. This XRAY reviews the underlying story about this early breast cancer vaccine trial. (10/25/19)
Read More
Personal Story : Running marathons with metastatic breast cancer? Yes!
Most relevant for: Women with metastatic breast cancer
Runner’s World Magazine featured Sarah Smith, a metastatic breast cancer patient who runs marathons and ultra-marathons. By telling her story, Sarah wants to encourage people to stay active, despite the challenges that life may bring. (10/13/19)
Read More
Relevance: Medium-High


Strength of Science: Medium-High


Research Timeline: Human Research


Study : Research on the PARP inhibitor talazoparib (Talzenna) for early-stage breast cancer is promising
Most relevant for: People with early stage breast cancer who have an inherited BRCA mutation
The PARP inhibitor talazoparib (Talzenna) has been useful for treatment of advanced or metastatic breast cancer for patients with BRCA mutations. A preliminary study showed that the majority of patients who took talazoparib alone before surgery for early-stage breast cancer had effective treatment and manageable side effects. Expanded clinical trials are in progress to verify this result. (10/4/19)
Read More
Relevance: Medium-High


Strength of Science: Medium


Research Timeline: Post Approval


Study : Inherited mutations in metastatic breast cancer patients
Most relevant for: People with metastatic breast cancer
Recent research shows that a significant portion of patients with metastatic breast cancer have harmful mutations in a gene associated with hereditary breast cancer and increased breast cancer risk. (9/26/19)
Read More
Guideline : FDA issues warning on CDK inhibitors
Most relevant for: People currently taking a CDK inhibitor
The U.S. Food and Drug Administration issued a safety alert for CDK inhibitors, including Ibrance (palbociclib), Kisqali (ribociclib), and Verzenio (abemaciclib). (9/24/19)
Read More
Study : Does eating meat affect breast cancer risk?
Most relevant for: Women with a family history of breast cancer
Eating meat has been suggested to increase breast cancer risk. The recent Sister Study looked at meat type, cooking methods and breast cancer risk in a study of 42,012 women. (9/10/19)
Read More.jpg?h=400&w=400&fit=contain&fm=webp)
Relevance: High


Strength of Science: High


Research Timeline: Post Approval


Study : Is it safe for BRCA mutation carriers to become pregnant following breast cancer?
Most relevant for: Women with a BRCA mutation who are considering pregnancy after breast cancer
New research shows that pregnancy after breast cancer is safe for women with BRCA mutations and their babies. (9/4/19)
Read More
Study : Supportive care can improve quality of life for people with metastatic breast cancer
Most relevant for: People diagnosed with metastatic breast cancer
Metastatic breast cancer patients have unique needs for treatment and care. Connecting patients to appropriate support services and palliative care is an area of need in health care. A recent study reported improvement in metastatic breast cancer patient quality of life and wellness with an intervention program called the Supportive, Education and Advocacy (MBC-SEA) program. (8/21/19)
Read More
Relevance: High


Strength of Science: Medium-High


Research Timeline: Post Approval


Study : MRI or mammograms for detecting breast cancer in families with unknown genetic mutations?
Most relevant for: People with a personal or family history of cancer where no mutation has been found
MRI and mammograms are used together to detect breast cancer in high-risk women who test positive for a BRCA or other gene mutation that increases the risk for breast cancer. For women with a family history of breast cancer but no known genetic mutation, increased screening is recommended. But what method is best? A recent clinical trial in the Netherlands compared MRI and mammography for this population. (8/15/19)
Read More